Clinical trial · Observational
Role of Omega-6 Fatty Acids in Hepatocellular Carcinoma Development.
Study of Omega-6 Fatty Acids in Patients With Hepatocellular Carcinoma
NCT07265076CI-TRIAL-00098409RO6-HCCnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study investigates the association between serum Omega-6 fatty acids and hepatocellular carcinoma development. Adult HCC patients and age - and gender matched healthy controls will be included. Serum Omega-6 levels will be compared between groups to explore potential correlations with disease presence and severity .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hpatocellular | Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Omega 6 fatty acid | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HCC Patients 50-100
- label
- HCC Patients Healthy Controls
- description
- HCC Patients: adult patients diagnosed with Hepatocellular carcinoma , meeting inclusion/exclusion criteria healthy controls: age and gender matched healthy adults with no history of liver disease
- interventionNames
- Dietary Supplement: Omega 6 fatty acid
Primary outcomes (1)
- measure
- Serum Omega-6 Fatty Acid Levels
- timeFrame
- At baseline
- description
- Measurement of circulating levels of Omega-6 fatty acids in blood samples of hepatocellular carcinoma patients and healthy controls using standardized laboratory techniques. The primary outcome will assess the association between serum Omega-6 concentrations and the presence of hepatocellular carcinoma.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Adults aged 18 years and above. 2. Patients with hepatocellular carcinoma (confirmed clinically, laboratory, radiologically, or histopathologically). 3\. Ability and willingness to provide informed written consent. 4. For healthy controls: individuals without liver disease or history of malignancy, matched by age and gender. 5\. For cirrhotic controls: patients with liver cirrhosis without evidence of any malignancy, matched by age and gender. Exclusion Criteria: 1. History of chronic inflammatory (except for liver cirrhosis or HCC) or autoimmune diseases. 2. Current use of omega-6 or omega-3 fatty acid supplements. 3. Presence of other types of cancer. 4. Pregnant or lactating women. 5. presence of severe comorbid condition. \-
References
Publications (0)
Data not yet available
No reference posted for this study.